poisar

Stocks · News reference

Why Is Arbutus Biopharma Stock Gaining Friday?

BenzingaVandana Singh

Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolReuben Gregg Brewer

    Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027

    Pfizer is addressing patent cliff concerns with 32% revenue growth from new and acquired drugs in Q3 2026. Despite investor pessimism reflected in a 6.1% dividend yield, the company maintains financial strength with $1.8B in cash and $12.4B in short-term investments. Management is committed to maintaining and growing its dividend, supported by strong cash flow metrics.

  2. Globenewswire IncNa

    SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement

    SRX Global commented on industry activity in engineered T-cell therapies following Pfizer's $330 million upfront deal with Starna Therapeutics for pre-IND CAR-T programs. SRX is proceeding with its pending acquisition of CERo Therapeutics, which is advancing CER-1236, a clinical-stage engineered T-cell therapy currently in Phase 1/1b CERTAIN-T trials with seven patients dosed and no dose-limiting toxicities reported.

  3. The Motley FoolAdria Cimino

    Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027

    Both mRNA pioneers are transitioning beyond COVID-19 vaccine revenues. Moderna is recommended as the better buy due to growing sales, an advancing personalized cancer vaccine (intismeran) showing 42% risk reduction in melanoma trials, and an expanding vaccine portfolio. BioNTech, while having strong cash reserves and a promising pipeline, faces leadership transitions and more distant revenue opportunities.